NO20091626L - MGLUR5-modulatorer - Google Patents

MGLUR5-modulatorer

Info

Publication number: NO20091626L
Authority: NO; Norway
Prior art keywords: compounds; mglur5 modulators; preparation; relates; mglur5
Prior art date: 2006-10-05

Application number

NO20091626A

Other languages

English (en)

Norwegian (no)

Inventor

Abdelmalik Slassi

Louise Edwards

Methvin Isaac

Peter Dove

Tan Xin

Tomislav Stefanac

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-05

Filing date

2009-04-23

Publication date

2009-05-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39032082&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091626(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-04-23 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2009-05-04 Publication of NO20091626L publication Critical patent/NO20091626L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Psychiatry (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Psychology (AREA)
Obesity (AREA)
Otolaryngology (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Addiction (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Nutrition Science (AREA)
Anesthesiology (AREA)
Child & Adolescent Psychology (AREA)

NO20091626A 2006-10-05 2009-04-23 MGLUR5-modulatorer NO20091626L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82832506P	2006-10-05	2006-10-05
PCT/IB2007/002784 WO2008041075A1 (fr)	2006-10-05	2007-09-25	Modulateurs de mglur5

Publications (1)

Publication Number	Publication Date
NO20091626L true NO20091626L (no)	2009-05-04

Family

ID=39032082

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20091626A NO20091626L (no)	2006-10-05	2009-04-23	MGLUR5-modulatorer

Country Status (21)

Country	Link
US (1)	US7772235B2 (fr)
EP (1)	EP2079730A1 (fr)
JP (1)	JP2010505809A (fr)
KR (1)	KR20090060328A (fr)
CN (1)	CN101547916A (fr)
AR (1)	AR062965A1 (fr)
AU (1)	AU2007303889B2 (fr)
BR (1)	BRPI0719155A2 (fr)
CA (1)	CA2665083A1 (fr)
CL (1)	CL2007002757A1 (fr)
CO (1)	CO6220935A2 (fr)
IL (1)	IL197722A0 (fr)
MX (1)	MX2009003227A (fr)
NO (1)	NO20091626L (fr)
NZ (1)	NZ575657A (fr)
PE (1)	PE20081378A1 (fr)
RU (1)	RU2439068C2 (fr)
SA (1)	SA07280518B1 (fr)
TW (1)	TW200821305A (fr)
UY (1)	UY30610A1 (fr)
WO (1)	WO2008041075A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009054786A1 (fr) *	2007-10-26	2009-04-30	Astrazeneca Ab	Dérivés de n-oxydes d'aryle 1,2,4-triazole utilisés en tant que modulateurs de mglur5
WO2009054794A1 (fr) *	2007-10-26	2009-04-30	Astrazeneca Ab	Dérivés d'amino1,2,4-triazoles en tant que modulateurs du mglur5
WO2009054787A1 (fr) *	2007-10-26	2009-04-30	Astrazeneca Ab	Dérivés d'acide 1,2,4-triazole carboxylique utilisés en tant que modulateurs de mglur5
TW200922586A (en) *	2007-10-26	2009-06-01	Astrazeneca Ab	Thiophene 1,2,4-triazole derivatives as modulators of mGluR5
WO2009054790A1 (fr) *	2007-10-26	2009-04-30	Astrazeneca Ab	Dérivés hétéroaromatiques à liaison amide utilisés en tant que modulateurs de mglur5
WO2009054785A1 (fr) *	2007-10-26	2009-04-30	Astrazeneca Ab	Dérivés d'éther de 1,2,4-triazole comme modulateurs de mglur5
CN102176910A (zh) *	2008-08-12	2011-09-07	阿斯利康(瑞典)有限公司	4-(5-{(1r)-1-[5-(3-氯苯基)异噁唑-3-基]乙氧基}-4-甲基-4h-1,2,4-三唑-3-基)吡啶的新晶体形式
MX2011001549A (es) *	2008-08-12	2011-03-15	Astrazeneca Ab	Forma cristalina de 4-(5-{(1r)-1-[5-(3-clorofenil)isoxazol-3-il]et oxi}-4-metil-4h-1,2,4-triazol-3-il)piridina.
KR20110101164A (ko) *	2008-12-18	2011-09-15	아스트라제네카 아베	1-〔5-(3-클로로-페닐)-이소옥사졸-3-일〕-에타논 및 (ｒ)-1-〔5-(3-클로로-페닐)-이속사졸-3-일〕-에탄올의 신규 제조 방법
US20100273805A1 (en) *	2009-04-23	2010-10-28	Astrazeneca Ab	Sulphide bridged derivatives as modulators of mglur5 733
JP2013505297A (ja) *	2009-09-21	2013-02-14	ヴァンダービルトユニバーシティー	ｍＧｌｕＲ５の正のアロステリック調節因子としてのＯ−ベンジルニコチンアミド類似体
WO2012058128A2 (fr) *	2010-10-28	2012-05-03	Merck Sharp & Dohme Corp.	Modulateurs caprolactames des récepteurs mglur5
AU2011338339A1 (en)	2010-12-08	2013-06-27	Vanderbilt University	Bicyclic pyrazole compounds as allosteric modulators of mGluR5 receptors
AU2011343477A1 (en) *	2010-12-17	2013-07-04	Vanderbilt University	Bicyclic triazole and pyrazole lactams as allosteric modulators of mGluR5 receptors
US8471027B2 (en)	2011-04-06	2013-06-25	Hoffmann-La Roche Inc.	Adamantyl compounds
EP2857387A1 (fr)	2013-10-07	2015-04-08	Boehringer Ingelheim International Gmbh	Procédé pour la préparation de l'acide 1,6-dihydro-6-oxo-pyridazine-4 carboxylique
WO2018010163A1 (fr) *	2016-07-15	2018-01-18	泸州东方农化有限公司	Procédé synthétique pour le composé 1,2,4-triazole-3-thione et son intermédiaire
AU2018334290A1 (en)	2017-09-18	2020-04-02	Goldfinch Bio, Inc.	Pyridazinones and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1894241A (zh) *	2002-08-09	2007-01-10	阿斯利康(瑞典)有限公司	作为代谢型谷氨酸受体－5调节剂的“1,2,4” 噁二唑
US7585881B2 (en) *	2004-02-18	2009-09-08	Astrazeneca Ab	Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
GB0420722D0 (en) *	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
GB0514296D0 (en)	2005-07-12	2005-08-17	Novartis Ag	Organic compounds
UY29796A1 (es) *	2005-09-29	2007-04-30	Astrazeneca Ab	Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
TW200811157A (en) *	2006-05-05	2008-03-01	Astrazeneca Ab	mGluR5 modulators I
TW200808800A (en) *	2006-05-05	2008-02-16	Astrazeneca Ab	MGluR5 modulators V

2007
- 2007-09-21 TW TW096135382A patent/TW200821305A/zh unknown
- 2007-09-24 SA SA07280518A patent/SA07280518B1/ar unknown
- 2007-09-25 NZ NZ575657A patent/NZ575657A/en not_active IP Right Cessation
- 2007-09-25 PE PE2007001288A patent/PE20081378A1/es not_active Application Discontinuation
- 2007-09-25 CA CA002665083A patent/CA2665083A1/fr not_active Abandoned
- 2007-09-25 WO PCT/IB2007/002784 patent/WO2008041075A1/fr not_active Ceased
- 2007-09-25 AU AU2007303889A patent/AU2007303889B2/en not_active Ceased
- 2007-09-25 US US11/902,784 patent/US7772235B2/en not_active Expired - Fee Related
- 2007-09-25 KR KR1020097006875A patent/KR20090060328A/ko not_active Withdrawn
- 2007-09-25 MX MX2009003227A patent/MX2009003227A/es not_active Application Discontinuation
- 2007-09-25 JP JP2009530956A patent/JP2010505809A/ja active Pending
- 2007-09-25 RU RU2009111113/04A patent/RU2439068C2/ru not_active IP Right Cessation
- 2007-09-25 CL CL200702757A patent/CL2007002757A1/es unknown
- 2007-09-25 CN CNA2007800451517A patent/CN101547916A/zh active Pending
- 2007-09-25 BR BRPI0719155-3A patent/BRPI0719155A2/pt not_active IP Right Cessation
- 2007-09-25 EP EP07804973A patent/EP2079730A1/fr not_active Withdrawn
- 2007-09-25 AR ARP070104214A patent/AR062965A1/es not_active Application Discontinuation
- 2007-09-25 UY UY30610A patent/UY30610A1/es not_active Application Discontinuation
2009
- 2009-03-19 IL IL197722A patent/IL197722A0/en unknown
- 2009-04-23 NO NO20091626A patent/NO20091626L/no not_active Application Discontinuation
- 2009-04-29 CO CO09043380A patent/CO6220935A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU2007303889B2 (en)	2011-02-24
AU2007303889A1 (en)	2008-04-10
SA07280518B1 (ar)	2011-01-15
CL2007002757A1 (es)	2008-06-20
AR062965A1 (es)	2008-12-17
WO2008041075A1 (fr)	2008-04-10
BRPI0719155A2 (pt)	2014-02-04
JP2010505809A (ja)	2010-02-25
CA2665083A1 (fr)	2008-04-10
PE20081378A1 (es)	2008-11-12
RU2439068C2 (ru)	2012-01-10
TW200821305A (en)	2008-05-16
CO6220935A2 (es)	2010-11-19
NZ575657A (en)	2011-03-31
IL197722A0 (en)	2009-12-24
MX2009003227A (es)	2009-04-06
UY30610A1 (es)	2008-05-02
AU2007303889A2 (en)	2010-07-15
RU2009111113A (ru)	2010-11-10
US20080125436A1 (en)	2008-05-29
EP2079730A1 (fr)	2009-07-22
US7772235B2 (en)	2010-08-10
CN101547916A (zh)	2009-09-30
KR20090060328A (ko)	2009-06-11

Publication	Publication Date	Title
NO20091626L (no)	2009-05-04	MGLUR5-modulatorer
NO20076059L (no)	2008-01-30	2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer
NO20092412L (no)	2009-08-19	Hydantoinderivater anvendes som MMP-inhibitorer
NO20081729L (no)	2008-05-16	Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
NO20081217L (no)	2008-04-15	Nye benzotiazolonderivater
NO20073572L (no)	2007-09-12	Nye forbindelser
MY148566A (en)	2013-04-30	Crystalline solvates and complexes of (is) -1, 5- anhydro-1 -c-(3-( (phenyl) methyl) phenyl) -d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes
NO20092689L (no)	2009-09-14	Quinuclidinolderivater som muskarin reseptorantagonister
NO20074592L (no)	2007-10-19	Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
NO20074093L (no)	2008-02-07	Fremgangsmater for fremstilling av glukopyranosyl-substituerte benzyl-benzenderivater og mellomprodukter derav
UA95644C2 (ru)	2011-08-25	Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
MX2010009752A (es)	2010-09-30	Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
NO20091599L (no)	2009-07-21	Kjemiske forbindelser
NO20055688L (no)	2006-01-09	Organiske forbindelser
TW200801003A (en)	2008-01-01	Novel compounds
NO20082496L (no)	2008-07-24	Pyrazinderivater
NO20084850L (no)	2008-12-02	MGLUR5 modulatorer I
NO20065456L (no)	2007-01-04	Substituerte morfolinforbindelser for behandling av sykdommer i sentralnervesystemet
SE0401762D0 (sv)	2004-07-05	Novel compounds
MY162022A (en)	2017-05-31	Chemical compounds 637: pyridopyrimidinediones as pde4 inhibitors
MX2010009022A (es)	2010-09-07	Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
TW200833670A (en)	2008-08-16	Novel compounds 569
NO20056192L (no)	2005-12-27	Kapaseinhibitorer og anvendelse derav
NO20080394L (no)	2008-03-14	N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav
IL183373A0 (en)	2007-09-20	3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof

Legal Events

Date	Code	Title	Description
2013-04-22	FC2A	Withdrawal, rejection or dismissal of laid open patent application